Review



selective fgfr2 inhibitor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress selective fgfr2 inhibitor
    (A) Relative expression levels of miR-671-5p after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). (B) Relative <t>Fgfr2</t> mRNA expression levels after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.
    Selective Fgfr2 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/selective fgfr2 inhibitor/product/MedChemExpress
    Average 93 stars, based on 2 article reviews
    selective fgfr2 inhibitor - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Circular RNA circSmad4 controls pulmonary fibrosis"

    Article Title: Circular RNA circSmad4 controls pulmonary fibrosis

    Journal: The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology

    doi: 10.4196/kjpp.25.123

    (A) Relative expression levels of miR-671-5p after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). (B) Relative Fgfr2 mRNA expression levels after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.
    Figure Legend Snippet: (A) Relative expression levels of miR-671-5p after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). (B) Relative Fgfr2 mRNA expression levels after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.

    Techniques Used: Expressing

    (A) Relative miR-671-5p amount in NIH3T3 treated with TGF-β1 (n = 6 per group). (B) Relative mRNA levels of fibrosis-related genes ( Acta2, Col1a1, Col3a1, Ctgf ) under the indicated combinations of miR-671-5p mimic and TGF-β1 (n = 6 per group). (C) Collagen concentrations measured in the culture medium (Media collagen) and the matrix-associated fraction (Matrix collagen) transfected with miR-671-5p mimic in NIH3T3 cells (n = 8 per group). (D) Relative Fgfr2 mRNA expression levels in NIH3T3 fibroblasts treated with TGF-β1 (n = 6 per group). (E) Effect of miR-671-5p mimic on TGF-β1-induced in Fgfr2 mRNA expression (n = 6 per group). (F) Effect of si-circSMAD4 on TGF-β1-induced increase in Fgfr2 mRNA expression (n = 6 per group). (G) Changes in the expression of Acta2, Col1a1, Ctgf, Fibronectin-1 ( Fn1 ) in NIH3T3 cells under FGFR2-IN-1 and TGF-β1 treatments (n = 7 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. ns, not significant. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.
    Figure Legend Snippet: (A) Relative miR-671-5p amount in NIH3T3 treated with TGF-β1 (n = 6 per group). (B) Relative mRNA levels of fibrosis-related genes ( Acta2, Col1a1, Col3a1, Ctgf ) under the indicated combinations of miR-671-5p mimic and TGF-β1 (n = 6 per group). (C) Collagen concentrations measured in the culture medium (Media collagen) and the matrix-associated fraction (Matrix collagen) transfected with miR-671-5p mimic in NIH3T3 cells (n = 8 per group). (D) Relative Fgfr2 mRNA expression levels in NIH3T3 fibroblasts treated with TGF-β1 (n = 6 per group). (E) Effect of miR-671-5p mimic on TGF-β1-induced in Fgfr2 mRNA expression (n = 6 per group). (F) Effect of si-circSMAD4 on TGF-β1-induced increase in Fgfr2 mRNA expression (n = 6 per group). (G) Changes in the expression of Acta2, Col1a1, Ctgf, Fibronectin-1 ( Fn1 ) in NIH3T3 cells under FGFR2-IN-1 and TGF-β1 treatments (n = 7 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. ns, not significant. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.

    Techniques Used: Transfection, Expressing



    Similar Products

    selective fgfr2 inhibitor  (MedChemExpress)
    93
    MedChemExpress selective fgfr2 inhibitor
    (A) Relative expression levels of miR-671-5p after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). (B) Relative <t>Fgfr2</t> mRNA expression levels after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.
    Selective Fgfr2 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/selective fgfr2 inhibitor/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    selective fgfr2 inhibitor - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    pan fibroblast growth factor receptor fgfr2 selective inhibitor nvp bgj398  (Selleck Chemicals)
    93
    Selleck Chemicals pan fibroblast growth factor receptor fgfr2 selective inhibitor nvp bgj398
    High <t>FGFR2</t> amplification and expression in CNCAS028 xenografts. CNCAS005, CNCAS008, CNCAS015, CNCAS018 and CNCAS028 tumors were resected from xenografts and then subjected to (A) single nucleotide polymorphism 6.0 and (B) U133 plus 2.0 gene chips. Mean ± standard deviation; n=5.
    Pan Fibroblast Growth Factor Receptor Fgfr2 Selective Inhibitor Nvp Bgj398, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pan fibroblast growth factor receptor fgfr2 selective inhibitor nvp bgj398/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    pan fibroblast growth factor receptor fgfr2 selective inhibitor nvp bgj398 - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Relative expression levels of miR-671-5p after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). (B) Relative Fgfr2 mRNA expression levels after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.

    Journal: The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology

    Article Title: Circular RNA circSmad4 controls pulmonary fibrosis

    doi: 10.4196/kjpp.25.123

    Figure Lengend Snippet: (A) Relative expression levels of miR-671-5p after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). (B) Relative Fgfr2 mRNA expression levels after treatment with the si-circSmad4 ± TGF-β1 (n = 8–9 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001.

    Article Snippet: FGFR2-IN-1 (HY-145230; MedChemExpress) was used as a selective FGFR2 inhibitor and dissolved in dimethyl sulfoxide to the desired concentrations.

    Techniques: Expressing

    (A) Relative miR-671-5p amount in NIH3T3 treated with TGF-β1 (n = 6 per group). (B) Relative mRNA levels of fibrosis-related genes ( Acta2, Col1a1, Col3a1, Ctgf ) under the indicated combinations of miR-671-5p mimic and TGF-β1 (n = 6 per group). (C) Collagen concentrations measured in the culture medium (Media collagen) and the matrix-associated fraction (Matrix collagen) transfected with miR-671-5p mimic in NIH3T3 cells (n = 8 per group). (D) Relative Fgfr2 mRNA expression levels in NIH3T3 fibroblasts treated with TGF-β1 (n = 6 per group). (E) Effect of miR-671-5p mimic on TGF-β1-induced in Fgfr2 mRNA expression (n = 6 per group). (F) Effect of si-circSMAD4 on TGF-β1-induced increase in Fgfr2 mRNA expression (n = 6 per group). (G) Changes in the expression of Acta2, Col1a1, Ctgf, Fibronectin-1 ( Fn1 ) in NIH3T3 cells under FGFR2-IN-1 and TGF-β1 treatments (n = 7 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. ns, not significant. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.

    Journal: The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology

    Article Title: Circular RNA circSmad4 controls pulmonary fibrosis

    doi: 10.4196/kjpp.25.123

    Figure Lengend Snippet: (A) Relative miR-671-5p amount in NIH3T3 treated with TGF-β1 (n = 6 per group). (B) Relative mRNA levels of fibrosis-related genes ( Acta2, Col1a1, Col3a1, Ctgf ) under the indicated combinations of miR-671-5p mimic and TGF-β1 (n = 6 per group). (C) Collagen concentrations measured in the culture medium (Media collagen) and the matrix-associated fraction (Matrix collagen) transfected with miR-671-5p mimic in NIH3T3 cells (n = 8 per group). (D) Relative Fgfr2 mRNA expression levels in NIH3T3 fibroblasts treated with TGF-β1 (n = 6 per group). (E) Effect of miR-671-5p mimic on TGF-β1-induced in Fgfr2 mRNA expression (n = 6 per group). (F) Effect of si-circSMAD4 on TGF-β1-induced increase in Fgfr2 mRNA expression (n = 6 per group). (G) Changes in the expression of Acta2, Col1a1, Ctgf, Fibronectin-1 ( Fn1 ) in NIH3T3 cells under FGFR2-IN-1 and TGF-β1 treatments (n = 7 per group). p-values were determined using Tukey’s HSD test following one-way ANOVA. All data are presented as mean ± SEM. ns, not significant. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.

    Article Snippet: FGFR2-IN-1 (HY-145230; MedChemExpress) was used as a selective FGFR2 inhibitor and dissolved in dimethyl sulfoxide to the desired concentrations.

    Techniques: Transfection, Expressing

    High FGFR2 amplification and expression in CNCAS028 xenografts. CNCAS005, CNCAS008, CNCAS015, CNCAS018 and CNCAS028 tumors were resected from xenografts and then subjected to (A) single nucleotide polymorphism 6.0 and (B) U133 plus 2.0 gene chips. Mean ± standard deviation; n=5.

    Journal: Oncology Letters

    Article Title: Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET -amplified patient-derived gastric cancer xenografts

    doi: 10.3892/ol.2015.3601

    Figure Lengend Snippet: High FGFR2 amplification and expression in CNCAS028 xenografts. CNCAS005, CNCAS008, CNCAS015, CNCAS018 and CNCAS028 tumors were resected from xenografts and then subjected to (A) single nucleotide polymorphism 6.0 and (B) U133 plus 2.0 gene chips. Mean ± standard deviation; n=5.

    Article Snippet: In a subsequent experiment, the CNGAS028 model was also treated with vehicle, 15 mg/kg PHA665752, the pan-fibroblast growth factor receptor (FGFR2) selective inhibitor NVP-BGJ398 (15 mg/kg once-daily, oral administration; Selleck Chemicals) or 30 mg/kg PHA665752 in combination with 15 mg/kg NVP-BGJ398, respectively.

    Techniques: Amplification, Expressing, Standard Deviation

    Expression level of p-MET, MET, p-FGFR2 and FGFR2 analyzed by western blotting in patient-derived gastric cancer models. (A) Expression levels of p-MET, MET, p-FGFR2 and FGFR2 in CNCAS005, CNCAS008, CNCAS015, CNCAS018 and CNCAS028 tumors. p-FGFR2, phosphorylated fibroblast growth factor receptor 2.

    Journal: Oncology Letters

    Article Title: Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET -amplified patient-derived gastric cancer xenografts

    doi: 10.3892/ol.2015.3601

    Figure Lengend Snippet: Expression level of p-MET, MET, p-FGFR2 and FGFR2 analyzed by western blotting in patient-derived gastric cancer models. (A) Expression levels of p-MET, MET, p-FGFR2 and FGFR2 in CNCAS005, CNCAS008, CNCAS015, CNCAS018 and CNCAS028 tumors. p-FGFR2, phosphorylated fibroblast growth factor receptor 2.

    Article Snippet: In a subsequent experiment, the CNGAS028 model was also treated with vehicle, 15 mg/kg PHA665752, the pan-fibroblast growth factor receptor (FGFR2) selective inhibitor NVP-BGJ398 (15 mg/kg once-daily, oral administration; Selleck Chemicals) or 30 mg/kg PHA665752 in combination with 15 mg/kg NVP-BGJ398, respectively.

    Techniques: Expressing, Western Blot, Derivative Assay

    Expression level of p-MET, MET, p-FGFR2 and FGFR2 analyzed by western blotting in patient-derived gastric cancer models. Expression levels of p-MET, MET, p-FGFR2 and FGFR2 in CNCAS028 tumor tissues resected 2 h following the final treatment with PHA665752 and/or NVP-BGJ398 on day 21 of the efficacy study. p-FGFR2, phosphorylated fibroblast growth factor receptor 2.

    Journal: Oncology Letters

    Article Title: Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET -amplified patient-derived gastric cancer xenografts

    doi: 10.3892/ol.2015.3601

    Figure Lengend Snippet: Expression level of p-MET, MET, p-FGFR2 and FGFR2 analyzed by western blotting in patient-derived gastric cancer models. Expression levels of p-MET, MET, p-FGFR2 and FGFR2 in CNCAS028 tumor tissues resected 2 h following the final treatment with PHA665752 and/or NVP-BGJ398 on day 21 of the efficacy study. p-FGFR2, phosphorylated fibroblast growth factor receptor 2.

    Article Snippet: In a subsequent experiment, the CNGAS028 model was also treated with vehicle, 15 mg/kg PHA665752, the pan-fibroblast growth factor receptor (FGFR2) selective inhibitor NVP-BGJ398 (15 mg/kg once-daily, oral administration; Selleck Chemicals) or 30 mg/kg PHA665752 in combination with 15 mg/kg NVP-BGJ398, respectively.

    Techniques: Expressing, Western Blot, Derivative Assay